APP and Alzheimer disease: These AD KI models offer a new opportunity to study AD pathology in vivo as they closely represent the physiological accumulation of Aβ, without the potential risk of artificial phenotypes associated with the transgenic overexpression of the Aβ precursor protein (APP) present in the first-generation AD models [31].